When applying the filters for income, 56% of the patients taking a GLP-1 had income under $40,000, thus showing that patients in lower socio-economic classes can receive the medication if clinical criteria are met
This is an educational overview, not medical advice
A 10 mg dose is 1.0 mL
This medication is intended for patients suffering from obesity and metabolic issues, such as type 2 diabetes
The oral version was previously available for diabetes management (under the brand name Rybelsus), but this new FDA approval specifically authorizes a high-dose oral formulation for chronic weight management
Rather than mimicking GHRH, it binds to the growth hormone secretagogue receptor (GHSR-1a) the same receptor your body's own hunger hormone, ghrelin, acts on